Compare MDXH & MYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MDXH | MYO |
|---|---|---|
| Founded | 2003 | 2004 |
| Country | Belgium | United States |
| Employees | N/A | N/A |
| Industry | | Industrial Specialties |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.1M | 33.3M |
| IPO Year | 2021 | 2017 |
| Metric | MDXH | MYO |
|---|---|---|
| Price | $0.76 | $1.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $7.67 | $7.67 |
| AVG Volume (30 Days) | ★ 989.2K | 473.2K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,000,000,000.00 |
| Revenue This Year | $30.78 | $9.10 |
| Revenue Next Year | $18.31 | $13.59 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 40814.79 |
| 52 Week Low | $0.68 | $0.61 |
| 52 Week High | $5.33 | $3.04 |
| Indicator | MDXH | MYO |
|---|---|---|
| Relative Strength Index (RSI) | 14.92 | 68.31 |
| Support Level | $0.68 | $0.90 |
| Resistance Level | $2.30 | $1.13 |
| Average True Range (ATR) | 0.11 | 0.08 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 5.32 | 97.21 |
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA). Geographically, it derives maximum revenue from the United States, followed by Germany, and other international.